Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Shanghai Bangyao Biotechnology

Request full access

Through innovation led by gene editing, develop breakthrough human therapeutics and benefit the whole world

Minhang District, ChinaFounded 2013Biotech & Life Sciences

About Shanghai Bangyao Biotechnology

Shanghai Bangyao Biotechnology Co., Ltd. (BRL Medicine), established in 2013 by co-founders Wu Yuxuan, Li Dali, and Du Bing, is a clinical-stage biopharmaceutical firm headquartered in Minhang, Shanghai. The company concentrates on the development of cell and gene therapies aimed at treating cancers, genetic diseases, and autoimmune disorders. Its establishment was followed by a significant milestone in 2016 with its recombination and the creation of the "Shanghai Research Center for Gene Editing and Cell Therapy" in partnership with a university, solidifying its research foundation.

The company's business revolves around its robust research and development pipeline, leveraging CRISPR-Cas9 gene-editing technology to create novel treatments. BRL Medicine's strategy includes initiating multiple Investigator-Initiated clinical Trials (IIT) in prominent Chinese hospitals to validate its therapies. As a venture capital-backed, privately held company, its financial model relies on securing funding from institutional investors to advance its pipeline through preclinical and clinical stages. To date, the company has raised $55.6M and is backed by investors such as the Free Trade Zone Fund, Xiaomiao Langcheng, and CSPC Pharmaceutical Group.

BRL Medicine has developed five core technology platforms with independent intellectual property rights: the Gene Editing Technology Innovation Platform (CRISTARS®), Hematopoietic Stem Cell Platform, Quikin CAR-T Platform (Quikin CART®), Universal Cell Platform (TyUCell®), and an Enhanced T Cell Platform. These platforms are the engine for its product development, which includes therapies for beta-thalassemia and various cancers. For instance, its CRISTARS® platform is dedicated to creating advanced DNA base editing tools, while the TyUCell® platform focuses on allogeneic immune cells to create generalized, cost-effective cell therapy products. The company has successfully advanced several projects, with five receiving IND approvals and numerous publications in high-impact journals like Nature Medicine and Nature Biotechnology, detailing excellent clinical results for its gene editing projects for β-thalassemia and CAR-T therapies.

Source: Dealroom company data

At a glance

Status
Operational
Employees
9
Open positions
None listed
Dealroom signal
34.3/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES BOther financing Nov 2024 $28M $110M CSPC · Betta Biomedical Industry Fund ↗
SERIES BOther financing Nov 2022 $28M $110M Gopher Asset Management · Tasly Capital · Oriental Fortune Capital · Betta Biomedical Industry Fund ↗
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Shanghai Bangyao Biotechnology website traffic

Latest recorded traffic for Shanghai Bangyao Biotechnology is 1.3K monthly website visits, up 0% over the last three months. Shanghai Bangyao Biotechnology's team grew 0% over the past year.

Latest monthly visits1.3K 3-month web change0% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Shanghai Bangyao Biotechnology in the Minhang District ecosystem

Live from Dealroom

The Shanghai Bangyao Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A6 investors entered at this stage

  • FTZ Fund
  • Gopher Asset Management
  • Tasly Capital
  • Oriental Fortune Capital
  • Betta Biomedical Industry Fund
  • CSPC
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇨🇳 China100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Shanghai Bangyao Biotechnology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Shanghai Bangyao Biotechnology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.